Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.

Petratos S, Ozturk E, Azari MF, Kenny R, Young Lee J, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, et al.